Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Endocrine 2Thoracic 1Other 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 117Neoplasms 42Carcinoma, Neuroendocrine 34Carcinoma, Non-Small-Cell Lung 32Carcinoid Tumor 30Multiple Endocrine Neoplasia Type 1 28Melanoma 27Breast Neoplasms 27Colorectal Neoplasms 25Small Cell Lung Carcinoma 24Pancreatic Neoplasms 22Carcinoma, Renal Cell 22Gastro-enteropancreatic neuroendocrine tumor 21Neoplasm Metastasis 20Lung Neoplasms 19Sarcoma 18Carcinoma, Hepatocellular 18Adrenocortical Carcinoma 18Stomach Neoplasms 17Uterine Cervical Neoplasms 15Thyroid Neoplasms 15Thyroid Carcinoma, Anaplastic 15Thyroid Cancer, Papillary 15Pheochromocytoma 15Ovarian Neoplasms 15Carcinoma 14Prostatic Neoplasms 13Paraganglioma 13Head and Neck Neoplasms 13Colonic Neoplasms 13

Interventions

GSK3352589 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Irritable Bowel Syndrome × Endocrine × Clear all
NCT03154086 2019-08-09

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
68 enrolled 80 charts
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

NCT02727283 2017-05-08

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
16 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡